Shield Therapeutics plc (LON:STX – Get Free Report) shot up 11.3% during trading on Thursday . The company traded as high as GBX 2.70 ($0.03) and last traded at GBX 2.70 ($0.03). 5,886,581 shares traded hands during trading, an increase of 143% from the average session volume of 2,422,151 shares. The stock had previously closed at GBX 2.43 ($0.03).
Shield Therapeutics Price Performance
The stock has a 50 day simple moving average of GBX 2.70 and a 200-day simple moving average of GBX 3.24. The firm has a market cap of £21.12 million, a PE ratio of -67.50 and a beta of 1.42. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- Oracle Announces Game-Changing News for the AI Industry
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to trade using analyst ratings
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
